

**VA St. Louis Health Care System
Research and Development Service
Research Day 2023**

VA



U.S. Department
of Veterans Affairs

Table of Contents

VA St. Louis Health Care System	pg. 3
Message Dr. Ziyad Al-Aly, M.D., ACOS/Research Service	pg. 4
Introduction	pg. 5
Program Services	pg. 6
St. Louis Veterans Research and Education Foundation	pg. 7
VA St. Louis Research Service Leadership Team	pg. 8
Project Approval Pathway VA St. Louis Health Care System Research Subcommittees	pg. 10
Pre-Review and Education Program: The (PREP) Team	pg. 11
Secondary Review of VA Approved Research through the “Just in Time” Information Portal	pg. 12
Research Space	pg. 12
Clinical Trials Unit	pg. 13
Clinical Epidemiology Center	pg. 14
Checklist for Publishing VA Research	pg. 14
2023 VA St. Louis Health Care System Investigator of the Year Award	pg. 17
2023 VA St. Louis Health Care System Lifetime Achievement Award	pg. 17
List of VA Funded Studies	pg. 18
List of Non-VA Funded Studies	pg. 20
VA St. Louis Research Affiliated Principal Investigator Publications, 2022	pg. 23
2023 VHA ORD Submissions Calendar	pg. 30
Research and Development Service Directory	pg. 33

The VA St. Louis Health Care System

The VA St. Louis Health Care System (VASTLHCS) is a full-service health care facility providing inpatient and ambulatory care in medicine, surgery, psychiatry, neurology, and rehabilitation, as well as over 65 subspecialty areas. It is a two-division facility that serves Veterans and their families in east central Missouri and southwestern Illinois.



John Cochran Division
915 North Grand Blvd., Saint Louis, MO 63106
Phone: 314-652-4100

The John Cochran Division, named after the late Missouri congressman, is located in midtown St. Louis in close proximity to its affiliated medical schools - Saint Louis University and Washington University. It has all of the medical center's operative surgical capabilities, the ambulatory care unit, and a six-story Clinical Addition that includes surgical facilities, intensive care units, outpatient psychiatry clinics, and expanded laboratory.



The Jefferson Barracks Division is a multi-building complex overlooking the Mississippi River in south St. Louis County. It provides psychiatric treatment, regional spinal cord injury treatment, a nursing home care unit, geriatric health care, rehabilitation services, and a rehabilitation domiciliary program for homeless Veterans.

Jefferson Barracks Division
#1 Jefferson Barracks Drive, Saint Louis, MO 63125
Phone: 314-652-4100

The VA St. Louis Health Care System is associated with the following Community Based Outpatient Clinics (CBOCs)

- Franklin County VA Clinic, Washington, MO
- Manchester Avenue VA Clinic, St. Louis, MO
- Olive Street VA Clinic, St. Louis MO
- St. Charles County VA Clinic, O'Fallon, MO
- St. Clair County VA Clinic, Shiloh, IL
- St. Louis County VA Clinic, Florissant, MO
- Washington Avenue VA Clinic, St. Louis, MO

VA Research & Development Program

An Enduring Commitment to Veterans



Ziyad Al-Aly, M.D., FASN

For more than 95 years, Veterans Affairs (VA) Research has advanced beyond anything early VA researchers could have imagined. VA Research is designed to directly address the health issues affecting Veterans and improve their lives in tangible and significant ways. It also affects the lives of all Americans through health care discovery and innovation.

VA Research is unique because of its focus on health issues that affect Veterans. It is a part of an integrated health care system with a state-of-the-art electronic health record and has come to be viewed as a model for superior bench-to-bedside research. Our research deals with many current topics that are critical to today's Veterans including the following: the chronic effects of neurotrauma; VA's Million Veteran Program (genomics); pain and opioid research; PTSD; prosthetics; rehabilitation engineering; spinal cord injury; suicide prevention; traumatic brain injury (TBI); VA clinical trials; Vietnam Veterans' research and female Veterans' research.

VA Research fosters dynamic collaborations with academia, other federal agencies, non-profit organizations, and private industry, thus furthering the program's impact on the health of Veterans and the nation.

We hope this booklet gives you an overview of our St. Louis VA Research Program and an understanding of the scope and impact of the work being done by talented, dedicated investigators at the St. Louis VA. Thanks to their brilliant efforts and the many Veterans who volunteer to take part in VA research, we proudly carry forth our long-standing tradition of discovery, innovation and advancement.

Sincerely,

Ziyad Al-Aly, M.D., FASN

Associate Chief of Staff

Research Service

VA St. Louis Health Care System
Research and Development Service
501 North Grand Blvd.
St. Louis, MO 63103
314-289-6333

Introduction

VA Research fosters dynamic collaborations with its university partners, other federal agencies, nonprofit organizations, and private industry — thus furthering the program's impact on the health of Veterans and the nation.

The VA St. Louis Health Care System (VASTLHCS) Research and Development Service supports VA investigators by working with them to develop health-related research applications within an area that is relevant to the care of Veterans. Research funding is awarded to VA medical centers on behalf of principal investigators to facilitate the pursuit of a scientific objective. VA Office of Research and Development (ORD) issues targeted funding opportunity announcements (FOAs) and requests for applications (RFAs) for research addressing specific Veterans' health care issues.

Our VA Program is unique in that it is the only research program focused on conducting pioneering research to meet the full scope of Veterans' medical needs.

It has become an admired model for conducting the highest quality of research. VA research not only benefits Veterans but improves healthcare to the entire nation through innovation and discovery.

Our Research Program in St. Louis has approximately 125 active studies. We reported approximately \$4.5M in annual spending in FY22. Our Program continues to attract the best and brightest researchers, most of whom are VA clinicians and are able to promote the rapid translation of research findings into advancements in care. We continue to embrace continuous improvement, working closely with the VA Office of Research and Development (ORD) and Office of Research Oversight (ORO) to adopt best practices seen across the VHA research enterprise. Our administrative staff brings these best practices to our Subcommittees to help improve efficiency in our processes and quality of outcomes for the Veterans we serve.

The research process in VA starts with a tight focus on the everyday health needs and concerns of Veterans, and with consultation with national and regional VA clinical leaders. Solutions are identified and developed through careful, rigorous research in labs and clinics, and sometimes in the community. These solutions are then applied to patient care, or translated into new or improved programs, as rapidly as possible.

Requests for Applications (RFAs) are the appropriate mechanism for investigator-initiated VA research. The Merit Review Award Program is an intramural funding mechanism to support investigator-initiated research conducted by eligible VA-ORD investigators at VA medical centers (VAMCs) or VA-approved sites.

- Our investigators submitted over 20 Merit Review Award applications in 2022 to the Biological Laboratory Research & Development, Clinical Science Research & Development and Health Service Research & Development Services.

Veterans Health Administration Office of Research and Development Program Services

The Office of Research and Development (ORD) consists of four research services that together form a cohesive whole to explore all phases of Veterans' health care needs. Each service oversees a number of research centers of excellence.

Each of these four services is headed by a director who is supervised by the Chief Research and Development Officer (CRADO), who in turn reports to the Deputy Under Secretary for Health for Policy and Services. The four services are listed below with a brief description.

The [Biomedical Laboratory Research & Development Service](#) (BLR&D) conducts research that explores basic biological or physiological principles in humans or animals but does not involve intact human beings. For example, it includes research on animal models and investigations of tissues, blood or other biologic specimens from humans.

The [Clinical Science Research and Development Service](#) (CSR&D) conducts research that focuses on intact human beings as the unit of examination. Examples include interventional and effectiveness studies, clinical, epidemiological and technological studies.

The [Health Services Research and Development Service](#) (HSR&D) pursues research at the interface of health care systems, patients and health care outcomes. HSR&D underscores all aspects of VA health care; specifically, quality, access, patient outcomes and health care costs.

The [Rehabilitation Research & Development Service](#) (RR&D) is dedicated to the well-being of America's Veterans through a full spectrum of research: from approved rehabilitation research projects, through evaluation and technology transfer to final clinical application.

Overview of Research Awards, Budget Caps and Duration:

Merit Review Awards

BLR&D & CSR&D: \$165K/yr, yr1 -yr4
HSR&D: \$1.2M / maximum 4 yrs
RR&D: \$1.2M / maximum 4 yrs

Research Career Development Awards

BLR&D & CSR&D: PI salary support & \$105K/yr1 - \$75K/yr, yr2 – yr5.
HSR&D: PI salary support & \$40K/yr, yr1 – yr3
RR&D PI salary support & \$75K/yr, yr1 - yr5

All current VHA ORD Requests for Applications (RFAs) can be found on the VA [intranet](#) at [RFA's and Program Announcements](#) or by contacting Todd Kliche, Research Service Grants Manager at todd.kliche@va.gov.

The VA Research and Development Program is an intramural program to fund research conducted by VA-salaried investigators at VAMCs or VA-approved sites, managed at the highest level by the VHA Office of Research and Development (ORD). A Principal Investigator (PI) shall hold an MD, PhD, or equivalent doctoral degree in a medical, biological, or behavioral science field.

All PIs must have a VA paid appointment of at least 25 hours per week (5/8^{ths}) to receive ORD research funding (VHA Handbook 1200.15) through a VA grant mechanism. The VA employment status of each PI must be indicated in the grant application. If a clinician PI does not have a current, 5/8^{ths} VA paid appointment then a Director's Letter of Support from the Medical Center Director must include a commitment to offer the PI at least a 5/8^{ths} VA paid appointment at the VAMC. This is conditional upon approval of the grant application for funding.

Alternatively, eligible PI's may apply to the ORD Career Development Program (VHA Program Guide 1200.04). The Career Development Award (CDA) was established to mentor junior researchers, so they can learn from renowned, experienced VA researchers. Each of the 4 ORD Services offers a CDA program. Once accepted into the CDA program, through the Letter of Intent process, PIs may apply to specific RFAs which provide salary support in addition to funding for the research proposal.

In addition, ORD provides support to non-clinicians through the Research Career Scientist Program (VHA Program Guide 1200.20). Recognizing the importance of non-clinician researchers in improving the care of Veterans, ORD offers a process for qualified individuals who have a PhD in a medical, biological, or behavioral science field.

Information on all of the forementioned programs is available by contacting Todd Kliche, Research Service Grants Manager at todd.kliche@va.gov.

St. Louis Veterans Research and Education Foundation



The St. Louis Veterans Research and Education Foundation (VREF) has worked diligently alongside the VA St. Louis Health Care System since 1994. This relationship has resulted in astounding research outcomes and data on Veteran centric care. One such example of those results was clearly evidenced by the SPRINT study. This study had such an impact that the NIH chose to publish early results which alerted doctors to change treatment protocols for all patients with high blood pressure.

The VREF portfolio has continued to grow at an incredible pace each year and is the portal for applications for grants and projects outside of the VA to which a PI may apply. VREF also works

closely with the medical and pharmaceutical industry who offer clinical trials that clearly add benefit to the care of Veterans.

VREF is currently administering 38 active research projects with 31 occurring at St. Louis VA Clinical Trials Unit (CTU). This work is possible due to the strong support provided to the Foundation from the VA St. Louis Health Care System and specifically Dr. Al-Aly's staff within the Research and Development Service.

More information regarding VREF research opportunities, events to attend or ways to donate can be located at:

- Facebook www.facebook.com/VREFSTL
- Instagram @veteransresearch
- Twitter @VREFSTL
- Website www.vrefstl.org
- Or by contacting **Allison Shafer, VREF Executive Officer** at Allison.Shafer@va.gov

[Donate Now! - Veterans Research and Education Foundation of St Louis \(vrefstl.org\)](http://www.vrefstl.org)

Veterans Research & Education Foundation
501 N. Grand Boulevard Suite 300
St. Louis, Missouri 63103

VA St. Louis Health Care System, Research and Development Service Leadership Team

Dr. Ziyad Al-Aly, M.D., Associate Chief of Staff, Research Service (ACOS/R)

Ziyad.Al-Aly@va.gov

Susan Wood, Administrative Officer, Research Service (AO/R)

Susan.Wood3@va.gov

Kendrick Coleman, Administrative Officer, Research Service Clinical Trials Unit (AO/CTU)

kendrick.coleman@va.gov

Gary Schofield, RN, Research Service Nurse Manager

Gary.Schofield@va.gov

Alysha Hunter, Research Service Management Analyst

Alysha.Hunter@va.gov

Erin Olson, Research Service Budget Analyst

Erin.Olson@va.gov

Todd Kliche, Research Service Grants Manager

Todd.Kliche@va.gov

Research and Development Service Mission Critical Colleagues

Sandy Prosize, Research Compliance Officer (RCO) Sandra.Prosize@va.gov.

Sandy has recently accepted the position of RCO at VASTLHCS. Prior to this she served as the Subcommittee Administrator for our IACUC, SRS and IRB. Her position reports to the ORO through the

Medical Center Director as part of our Quality Management Service. Thus, providing an independent, third-party reviewer of research activities. She brings her operational knowledge of the research enterprise to her new role of ensuring its compliance with all VHA Guidance.

Paige Zimerman, Technology Transfer Specialist Paige.Zimerman@va.gov.


Prior to accepting the position of Field Technology Transfer Specialist, Paige served as the Research Service Management Analyst. Currently Paige reports to the Office of Research and Development (ORD) [Technology Transfer Program \(TTP\)](#) serving all VA medical centers in Missouri and Kansas. The mission of TTP is to facilitate the commercialization of VA technology and inventions to benefit our Nation's Veterans and the American public. TTP strives to achieve this goal by educating VA employees concerning their rights and obligations with respect to the development of technology, evaluating VA-developed technology and in turn invention disclosures, applying for intellectual property protection and assisting in the commercialization of new products. TTP has also begun to fund, manage and lead research and development throughout the VA to better commercialize VA-developed technology.



Marie White, RN and Linda Schimmoeller, RN
CTU Study Coordinators



Fahreta Hamzabegovic, IRB Administrator




Kendrick Coleman, AO/R CTU

Project Approval Pathway VA St. Louis Health Care System Research Subcommittees



PI received a favorable score for their grant application from ORD and Subsequent Notice of Award (NoA), submits project components to relevant subcommittees.



Institutional Review Board (IRB) serves as the primary reviewer for all projects that involve the use of human subjects as described by the Revised Common Rule and Veterans as described by VHA 1200.05.

Subcommittee Administrators

Fahreta Hamzabegovic & Natalie Niceforo
(STL.IRB.Admin@va.gov)

Chair: Dr. Chandra Reddy, M.D.
(Chandra.Reddy@va.gov)

The IRB is currently managing 28 active studies. **Dr. Chandra Reddy, M.D.**, has led the IRB through significant reorganization in 2022 with the additional of several new members creating a highly engaged Board.



The Subcommittee for Research Safety (SRS) serves as the primary reviewer for the safety components of all VA approved research occurring on site or at our affiliated medical schools.

Subcommittee Administrator

Erin Torrence (Erin.Torrence@va.gov)

Chair: Dr. Jacki Kornbluth, PhD (Jacki.Kornbluth@va.gov)

Dr. **Jacki Kornbluth, PhD**, continues oversight of the safety aspect of our research studies per VHA 1200.08(1). The SRS reviews reports regarding laboratory inspections, emergency preparedness, biosafety and security, vulnerability assessments, and chemical inventories. This responsibility includes VA research conducted on site as well as those conducted at affiliated universities.

The Institutional Animal Care and Use Committee (IACUC) serves as the primary review for all Animal Components of a Research Protocol (ACORP) present in VA approved research.

Subcommittee Administrator

Erin Torrence (Erin.Torrence@va.gov)

Chair: Dr. Marc Levin, M.D. (Marc.Levin2@va.gov)

As the VA St. Louis Health Care System does not operate an animal research facility, Dr. Levin and his subcommittee continue to provide oversight of all VA research involving animals occurring at our affiliated medical schools per VHA 1200.07.



Once informed of the RDC's decision to approve a project, **Dr. Ziyad Al-Aly, ACOS/R&D** will release an ACOS Implementation Memo to the PI authorizing the VA Research to begin.



The Research and Development Committee (RDC) is responsible for final approval of all VA Research which is pursuant to the approval of each component of the project by the relevant subcommittees per VHA 1200.01.

Subcommittee Administrator

Denise Garnett (Denise.Garnett@va.gov)

Chair: Dr. Fred Metzger, PhD (Fredric.Metzger@va.gov)


Dr. Fredric Metzger, PhD, continues to oversee the Research Program. In 2022, 23 new human and animal studies were submitted to the RDC for review and approval, along with many continuing reviews. The RDC also works with the VA Central IRB to monitor multi-site studies which are being performed in St. Louis.

Pre-Review and Education Program: The (PREP) Team

For more than 5 years the PREP Team has helped improve the efficiency of the approval process of VA research at the VA St. Louis Health Care System through their close work with PI's and all of the Research Service Subcommittee Administrators. The process was instituted to aid investigators through regulatory committee submissions and ultimately get studies off the ground more quickly. The goal of the process is fourfold: **1) assist in study feasibility assessment 2) guide study teams through the committee application process 3) identify and assess required resources 4) provide initial regulatory compliance overview.** Investigators are supported through the new study application steps by the PREP Team. The team meets with the investigators early in the submission process to help identify and resolve potential approval and startup barriers and assist teams with committee application forms. The pre-review process has proven to help alleviate study implementation slowdowns, improve regulatory compliance, as well as significantly decrease the timeline of study approvals from start to finish and the administrative workload of the Institutional Review Board. The PREP Team is unique to our Station and has been recognized by ORO and ORD during oversight visits as a best practice.



Amy Garner, Rebecca Kammer, Emilee Nealy



Secondary Review of VA Approved Research through the “Just in Time” Information Portal

Principal Investigators (PIs) may not commence performance of specific aims of an application selected for funding, until and unless applicable regulatory and other documents are reviewed and approved in the Just in Time (JIT) portal to ensure all VA regulations/policies are met. At a minimum, the PI will be asked to provide a VA Quad Chart which is a single Power Point slide containing several data points regarding the project, the ACORP once approved by VA St. Louis Research Service IACUC and Other Support documentation.

The expectation from ORD to the Station and PI is this process will be completed no more than 180 days from the time it populates in eRA Commons / JIT. Failure to complete this review can result in withdrawal of the Notice of Award. Funds will not be released by ORD until all JIT requests have been adjudicated.



Research Space

It is expected that the PI and VA co-investigators will perform all of the funded research in VA space or VA-leased space. However, if any of the proposed work will be carried out in non-VA space assigned to (or controlled by) a PI or VA investigator, a waiver to perform the research off-site must be obtained prior to submitting the application

Work performed in a non-VA collaborator’s off-site laboratory or off-site core facility does not require an off-site research waiver, except when a VA investigator is the core facility director. Guidelines for submitting an application for an off-site research waiver are described in the VHA Handbook 1200.16, VA Off-site Research Handbook. Requests for off-site waivers should be submitted by the due dates listed in the ORD submission calendar.

The VASTLHCS has space for research activities spread across the medical facility. This includes labs and offices at the John Cochran Division in Building 7A and Building 1 on various floors with new offices on floor 9 to be opened soon. Our Research Administration Office is located at 501 North Grand Boulevard, St. Louis, MO, 63103. The VASTLHCS has VA-leased space at Saint Louis University’s Doisy Building and VA-approved space in various buildings at Washington University.

Clinical Trials Unit

The St. Louis VA Health Care System's Clinical Trials Unit (CTU) continues to conduct research studies that have contributed to saving and improving the quality of life of our Veterans. Our commitment to the principals of **ICARE** (**I**ntegrity, **C**ommitment, **A**dvocacy, **R**espect, and **E**xcellence) are reflected in VA Research. Within the CTU, **WE CARE** about our patients by **W**elcoming them to our facilities and our Clinical Trials, **E**xplaining who we are and what we do, **C**onnecting with them to know who they are, **A**ctively listening to them, **R**esponding to them with dignity and respect and **E**xpressing gratitude for their service.



Lindsey Vargo, Janine Kampelman RN, Gary Schofield RN, Brittany Minor, Patrice Simpson, and Carley Browning



April Phipps, Study Coordinator

Our Veterans are generous enough to participate in our studies. The clinical trials being conducted in the CTU focus on lung and prostate cancer, spinal cord injuries, gout, diabetes and coronary artery disease, Parkinson's disease, Alzheimer's disease and several other areas of interest. **Kendrick Coleman, Administrative Officer (AO) / CTU** (kendrick.coleman@va.gov), currently provides oversight to 34 active studies with 12 more projects in the startup phase occurring in the CTU. Along with Kendrick is **Gary Schofield, R.N., Nurse Manager** (Gary.Schofield@va.gov) who also provides support to an outstanding group of 20 Research Coordinators who are

managing one or more research studies at any given time. Collectively, the CTU holds numerous years of research experience, familiarity with the VA healthcare system, and are dedicated to the care of Veterans.

Notable Research: The CTU continues to demonstrate its flexibility in supporting research activities beyond local VA Research to include themselves as a participating site in numerous multi-site studies sponsored at a Federal level. Since 2021 Dr. Eric Knoche, M.D. has been the Site Principal Investigator for 4 projects managed by the National Institutes of Health, National Cancer Institute Central Institutional Review Board (NCI-CIRB). In 2021 Dr. Ted Thomas, M.D. became the Site Principal Investigator for the Department of Veterans Affairs Lung Precision Oncology Program (LPOP) adding St. Louis to a list of 21 other VA Medical Centers contributing to the advancement of precision oncology. These



Danielle Tate, CTU Program Support Assistant

examples highlight how research conducted at the St. Louis VA is contributing to scientific findings assessed at a national level.

Clinical Epidemiology Center

The Clinical Epidemiology Center (CEC) at the Saint Louis VA Health Care System (VASTLHCS) began its operations in July 2013 thanks to a Department of Veterans Affairs T21 grant. The CEC is a core resource available to VA investigators to support and grow clinical epidemiology research at the VASTLHCS. Since its inception, the CEC has offered seminars organized around topics of interest within clinical epidemiology including lectures on novel concepts in biostatistics, epidemiology, data visualization, presentations of current research results, and hands-on seminars in statistics, grant writing, and proposal preparation.

The Clinical Epidemiology Center has been established to provide investigators working with the St. Louis VA with systematic support in building their research capacity, and in turn, the research capacity of the VA in order to improve the health of Veterans nationwide. It interfaces with the VA Informatics and Computing Infrastructure (VINCI) to produce the following services:

- Research design
- Data analysis
- Results dissemination
- Training and education

Notable Research: In November 2020 Dr. Ziyad Al-Aly, M.D. and his study team leveraged the strength of the CEC in his project leading to the publication of a seminal paper Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. As the novel coronavirus pandemic – 2019 (COVID-19) has progressed, Dr. Al-Aly and his team have published an additional 23 papers on the topic in journals such as Nature, Nature Medicine, and The Journal of the American Medical Association. His work has led to a worldwide collaborative effort to better understand the condition of Long COVID. Dr. Al-Aly’s team member Dr. Ulysses Labilles, PhD (Ulysses.Labilles@va.gov) leads a monthly lecture series on the topic providing a stage for subject matter experts to disseminate and discuss their initial findings.



Dr. Ulysses "Uly" Labilles

Checklist for Publishing VA Research

Below are requirements that authors must address when publishing research that was funded by VA or that used VA resources. Much of this information is covered in VHA Handbook 1200.19 – Presentation of Research Results. Note that the ORD service funding the study may have additional requirements; contact the specific service or review the ORD website for more information.

- **Acknowledge VA support**

If the work was funded by VA, include this statement: “This work was supported [or supported in part] by [type of award, e.g., Merit Review, Career Development Award, Pilot Project] Award # [award/project number, e.g., I01 RX000123] from the United States (U.S.) Department of Veterans Affairs [as applicable, indicate Biomedical Laboratory Research and Development Service; Clinical Sciences Research and Development Service (mention the CSR&D Cooperative Studies Program if applicable); Rehabilitation Research and Development Service; or Health Services Research and Development Service].” If VA only provided resources (e.g., facilities or patients), include this statement: “This material is the result of work supported with resources and the use of facilities at the [name and location of VA medical facility].”

- **Acknowledge VA employment**

Acknowledge employment of VA authors with VA title, name of VA medical facility, city, and state. Academic affiliate appointments can also be listed, but if research was funded only by VA, the VA affiliation should be listed first.

- **Include DVA/US Government disclaimer**

“The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.”

- **Link to clinicaltrials.gov**

If your publication concerns a clinical trial or observational study that was registered on clinicaltrials.gov, include the NCT number in the publication. This allows the clinicaltrials.gov website to link your paper to the trial registration.

- **Deposit your manuscript in PubMed Central if the study was VA-funded**

See guidance at: www.research.va.gov/resources/policies/public_access.cfm

- **Notify ORD through PubTracker**

Upon the paper’s acceptance, notify ORD Communications through the VA [PubTracker](#). This allows ORD to prepare media announcements, as appropriate, and to collect data regarding productivity of the VA Research program. Please note that this step also applies to meeting presentations.

Why work with the VA St. Louis Research Service?

St. Louis VA research has produced advancements in healthcare for Veterans:

Over 100 Affiliated Research Investigators

Approximately 170 active studies

Approximately \$4 million in Research expenditures annually

Research Strengths

Large cadre of accomplished researchers

Dual affiliation with Washington University & Saint Louis University

Responsive Executive and Administrative Team

Activated and engaged research committee chairs and members

Research is performed at:

John Cochran Division

Jefferson Barracks Division

Big Brother Big Sisters Building

Saint Louis University's Doisy Building (VA leased space)

Washington University's VA research investigators' labs (VA approved space)

Computer System

Our researchers have dedicated research servers that are employed for capture, assemblage, retrieval and analysis of all data related to research at the VASTLHCS. The research servers are located on the campus of the VASTLHCS. They meet all VA security requirements and are behind the VA firewall. Maintenance and analysis of our databases on these servers will markedly reduce security risks related to storage of protected health information or portable devices and enhance computer storage and data processing capabilities. Password protected access to the databases will be limited to approved personnel.

2023 VA St. Louis Health Care System Investigator of the Year Award

Dr. Sarah George, M.D.



VA Staff Physician, St. Louis VA Medical Center 2003-present


Professor of Internal Medicine, Division of Infectious Diseases, Allergy, and Immunology, Saint Louis University 2022-present

PI on more than 10 vaccine or treatment clinical trials including;

- A Phase I, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Yellow Fever Vaccine in 18-45 Year Old Healthy Adults, NIH/NIAID, June 2015-present.
- A Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine in Flavivirus Naïve Adult Subjects, NIH/NIAID, March 2017-present.
- Determine if a Candidate Dengue Vaccine in Advanced Trials Induces Antigen-Specific Cellular Immunity That Mimics Immunity After Multiple Infections and Controls Antibody-Enhanced Viral Replication, VHA/ORD, July 2017-present.
- A Phase 3 Safety, Immunogenicity, and Lot-Consistency Trial of the VLP-Based Chikungunya Vaccine in Healthy Adults and Adolescents, Emergent Biosolutions, July 2021-December 2022.
- Durability and Mechanisms of Dengue Vaccine and Infection Mediated Immunity, VHA/ORD, projected start October 2023.

2023 VA St. Louis Health Care System Lifetime Achievement Award

Dr. Douglas Mann, M.D.



Ada L. Steiner Professor of Cardiology, Professor of Medicine, Cell Biology and Physiology, Washington University School of Medicine 2019 – present

- Leader in cardiac cellular and molecular physiology, innate immunity and inflammation and heart failure.
- Bibliography includes over 400 peer reviewed articles and editorials published, 1984 – present
- Funding has included collectively over 55 grants, federal and non-federally funded, contracts for research and development and clinical trials.
- Served as mentor for 46 research fellows from 1991 - present.

VA Funded Studies

Ziyad Al-Aly, MD

- Cause-specific mortality among users of proton pump inhibitor

Rachael Beard, MSN, M.Ed, EdD, RN

- Multisite replication of the transitional care model

Carlos Mizrachi-Bernal, MD

- Vitamin D and developmental origins of insulin resistance

Brian Dieckraefe, MD

- Circulating biomarkers for the detection of human liver diseases
- Novel Reg4-CD44 signaling pathway in colon cancer

Abinav Diwan, MD

- Targeting macrophage lysosome biogenesis program in cardiomyopathy and heart failure
- Mitophagy pathways in cellular cross-talk in the myocardium

Jill Elwing, MD

- CSP #577 – Colonoscopy vs fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM)

James Fleckenstein, MD

- Molecular pathogenesis of enterotoxigenic Escherichia coli infections

Sarah George, MD

- Determine if a candidate dengue vaccine in advance trials induces antigen-specific cellular immunity that mimics immunity after multiple infections and controls antibody-enhanced viral replication

Leslie Gewin, MD

- Epithelial Beta-catenin Signaling Improves Chronic Renal Injury

Amy Joseph, MD

- Storytelling to improve disease outcomes in gout: the STRIDE-GO study
- VA Rheumatoid Arthritis (VARA) Study

Peggy Kendall, MD

- B Lymphocytes in autoimmune disease

Jacki Kornbluth, PhD

- Molecular Characterization of Anti-Tumor Activity Mediated by Extracellular Vesicles Derived from Natural Killer Cells
- NKLAM: An RBR E3 ubiquitin ligase essential for regulation of innate immunity

Daniel Kriesel, MD

- Leukocyte trafficking in thoracic grafts

Mauricio Lisker, MD

- PREventing liver cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM Study)

Andrea Loiselle, MD

- Dissecting the Role of Dietary Protein on Monocyte/Macrophage mTOR

Spencer Melby, MD

- Contribution of inflammation and oxidative stress in pericardial fluid to postoperative atrial fibrillation after cardiac surgery

Jessi Hatfield, MD

- Project work as a determinant of health: a pragmatic trial of enhanced cognitive behavioral therapy to bolster competitive work and wellness in veterans with serious mental illness (WORKWELL)

Brian Muegge, MD

- Enteroendocrine cell reprogramming during intestinal injury

Jason Napuli, MD

- CSP-2009 Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response: The SCEPTER Trial

Jeanne Nerbonne, PhD

- Identification of novel cellular/molecular mechanisms and arrhythmia targets in heart failure

Christine Pham, MD

- Immune-mediated pathways in pathogenesis of abdominal aortic aneurysm

Varun Puri, MD

- Defining quality of care in lung cancer

Michael Rauchman, MD

- Mechanisms and treatment of kidney fibrosis

- Million Veteran Program (MVP)

Babak Razani, MD

- Harnessing the autophagy-lysosomal biogenesis response in macrophages to treat atherosclerosis

Rajan Sah, MD

- Ion channel regulation of pancreatic islet cell function

Katherine Tam, MD

- Prospective Survey for Healthcare Process Map

Robert White, MD

- CIRB 22-65 Vet-PD: The Veterans Parkinson's Disease Genetics Initiative

Gregory Wu, MD

- Role of CSF microglia in health and disease

Mohamed Zayed, MD

- CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms

Non-VA Funded Studies

Rachael Beard, MSN, M.Ed, EdD, RN

- Multisite replication of the transitional care model

Seth Eisen, MD, MSc

- Incidence of diabetes and infection in abatacept treated rheumatoid arthritis

Jesse Keller, MD

- Novel risk prediction model for checkpoint inhibitor related autoimmune toxicities

Eric Knoche, MD

- Study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 11-IIIa and 1118 (T>5cm N2) completely resected (RO) non-small cell lung cancer (NSCLC)
- A phase three, randomized, double blind, placebo-controlled study of Talazopari with Enzalutamide in castration-resistant prostate cancer
- A randomized, double-blind, placebo-controlled, multicenter phase III study of Olaparib plus Abiraterone relative to placebo plus Abiraterone as first-line therapy in men with metastatic castration-resistant prostate

Geetha Maddukuri, MD

- CSP 2008: Pentoxifylline in Diabetic Kidney Disease

Jay McDonald, MD

- CDC IRB and Implementation of the Expanded Access Program: “Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Orthopoxvirus Infections
- VA trauma infectious diseases outcomes study

Ammar Nasir, MD

- Evaluation of treatment strategies for severe calcific coronary arteries: orbital atherectomy vs. conventional angioplasty technique prior to implantation of drug-eluting stents

Medhat Osman, MD

- A Multi-Center, Open-Label, Randomized Phase 1/2 Study of Copper Cu64PSMA I&T Injection in Patients with Histologically Proven Metastatic Prostate Cancer
- An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Prospective comparison of pelvic CT or MRI plus 18F-NaF PET/CT to 18F – Fluciclovine PET/CT in VA prostate cancer patients with BCR and a negative 99mTc-MDP bone scan
- VISION: an international, prospective, open-label, multicenter, randomized phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (MCRPC), of 177Lu-PSMA-617

Jiafu Ou, MD

- A randomized, double-blind, placebo-controlled multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2PREVENT)
- Cardiovascular inflammation reduction trial
- Pragmatic evaluation of events and benefits of lipid-lowering in older adults

Nathan Ravi, MD

- Preclinical development of reverse-engineered vitreous substitutes

Kavitha Reddy, MD

- Implementation of a pragmatic trial of whole health team vs. primary care group education to promote non-pharmacological strategies to improve pain, functioning and quality of life in veterans

Molly Sachdev, MD

- ARTESiA (Apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation)

Martin Schoen, MD

- Antithrombotic therapy to ameliorate complications of COVID-19

Sarah Shia, MD

- Personalizing Cognitive Processing Therapy with a Case Formulation Approach to Intentionally Target Impairment in Psychosocial Functioning Associated with PTSD

Kaharu Sumino, MD

- Intervention study in overweight patients with COPD

Theodore Thomas, MD

- A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
- LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
- Phase 3 study of Pembrolizumab (MK-3475) in combination with concurrent Chemoradiation therapy followed by Pembrolizumab with or without Olaparib compared with concurrent Chemoradiation therapy followed by Duralumin in participants with unresectable, locally advanced, stage III Non-Small Cell Lung Cancer (NSCLC)

Emad Zakhary, MD

- Carotid revascularization and medical management for asymptomatic carotid stenosis

Mohammed Zayed, MD

- Randomized, multicenter, controlled trial to compare best endovascular versus best surgical therapy in patients with critical limb ischemia
- Best-real world outcomes in critical limb ischemia registry
- PET-MR imaging of natriuretic receptor C (NPR-C) in carotid atherosclerosis
- R01 MRI perfusion study

VA St. Louis Research Affiliated Principal Investigator Publications, 2022

Long COVID after breakthrough SARS-CoV-2 infection.

Al-Aly Z, Bowe B, Xie Y.

Nat Med. 2022 Jul;28(7):1461-1467. doi: 10.1038/s41591-022-01840-0. Epub 2022 May 25.
PMID: 35614233

Mental health in people with covid-19.

Al-Aly Z.

BMJ. 2022 Feb 16;376:o415. doi: 10.1136/bmj.o415.

PMID: 35172969

Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes-Reply.

Al-Aly Z, Xie Y.

JAMA Intern Med. 2022 Jan 1;182(1):93-94. doi: 10.1001/jamainternmed.2021.6334.

PMID: 34724023

Reg4 Interacts with CD44 to Regulate Proliferation and Stemness of Colorectal and Pancreatic Cancer Cells.

Bishnupuri KS, Sainathan SK, Ciorba MA, Houchen CW, Dieckgraefe BK.

Mol Cancer Res. 2022 Mar 1;20(3):387-399. doi: 10.1158/1541-7786.MCR-21-0224.

PMID: 34753802

Acute and postacute sequelae associated with SARS-CoV-2 reinfection.

Bowe B, Xie Y, Al-Aly Z.

Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.

PMID: 36357676

The US Department of Veterans Affairs Science and Health Initiative to Combat Infectious and Emerging Life-Threatening Diseases (VA SHIELD): A Biorepository Addressing National Health Threats.

Harley JB, Pyarajan S, Partan ES, Epstein L, Wertheim JA, Diwan A, Woods CW, Davey V, Blair S, Clark DH, Kaufman KM, Khan S, Chepelev I, Devine A, Cameron P, McCann MF, Ammons MCB, Bolz DD, Battles JK, Curtis JL, Holodniy M, Marconi VC, Searles CD, Beenhouwer DO, Brown ST, Moorman JP, Yao ZQ, Rodriguez-Barradas MC, Mohapatra S, Molina De Rodriguez OY, Padiernos EB, McIndoo ER, Price E, Burgoyne HM, Robey I, Schwenke DC, Shive CL, Przygodzki RM, Ramoni RB, Krull HK, Bonomo RA.

Open Forum Infect Dis. 2022 Dec 14;9(12):ofac641. doi: 10.1093/ofid/ofac641. eCollection 2022 Dec.

PMID: 36601554

Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer.

Khan S, Chang SH, Hicks V, Wang M, Grubb RL 3rd, Drake BF.

Prostate Cancer Prostatic Dis. 2022 Apr;25(4):707-712. doi: 10.1038/s41391-021-00475-5. Epub 2021 Nov 22.

PMID: 34811499

Emerging therapies in the management of Irritable Bowel Syndrome (IBS).

Elwing JE, Atassi H, Rogers BD, Sayuk GS.

Expert Opin Emerg Drugs. 2022 Mar;27(1):55-73. doi: 10.1080/14728214.2022.2052043. Epub 2022 Mar 16.
PMID: 35266839

Segmental Colitis Associated With Diverticulosis Masquerading as Polyploid-Appearing Mucosa in the Rectosigmoid Area on Endoscopy and as Focal Thickening on Imaging.

Nwankwo EC Jr, Khneizer G, Sayuk G, Elwing J, Havlioglu N, Presti M.
Cureus. 2022 Mar 7;14(3):e22930. doi: 10.7759/cureus.22930. eCollection 2022 Mar.
PMID: 35399418

Targeting the A3 adenosine receptor to prevent and reverse chemotherapy-induced neurotoxicities in mice.

Singh AK, Mahalingam R, Squillace S, Jacobson KA, Tosh DK, Dharmaraj S, Farr SA, Kavelaars A, Salvemini D, Heijnen CJ.
Acta Neuropathol Commun. 2022 Jan 29;10(1):11. doi: 10.1186/s40478-022-01315-w.
PMID: 35093182

Blood-brain barrier penetration of non-replicating SARS-CoV-2 and S1 variants of concern induce neuroinflammation which is accentuated in a mouse model of Alzheimer's disease.

Erickson MA, Logsdon AF, Rhea EM, Hansen KM, Holden SJ, Banks WA, Smith JL, German C, Farr SA, Morley JE, Weaver RR, Hirsch AJ, Kovac A, Kontsekova E, Baumann KK, Omer MA, Raber J.
Brain Behav Immun. 2023 Mar;109:251-268. doi: 10.1016/j.bbi.2023.01.010. Epub 2023 Jan 20.
PMID: 36682515

Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia.

Sheikh A, Tumala B, Vickers TJ, Martin JC, Rosa BA, Sabui S, Basu S, Simoes RD, Mitreva M, Storer C, Tyksen E, Head RD, Beatty W, Said HM, Fleckenstein JM.
Nat Commun. 2022 Nov 12;13(1):6886. doi: 10.1038/s41467-022-34687-7.
PMID: 36371425

Tumor necrosis factor α impedes colonic thiamin pyrophosphate and free thiamin uptake: involvement of JNK/ERK1/2-mediated pathways.

Anthony Muthu S, Sabui S, Sheikh A, Fleckenstein JM, Said HM.
Am J Physiol Cell Physiol. 2022 Dec 1;323(6):C1664-C1680. doi: 10.1152/ajpcell.00458.2022. Epub 2022 Nov 7.
PMID: 36342158

Enterotoxigenic Escherichia coli Degrades the Host MUC2 Mucin Barrier To Facilitate Critical Pathogen-Enterocyte Interactions in Human Small Intestine.

Sheikh A, Wangdi T, Vickers TJ, Aaron B, Palmer M, Miller MJ, Kim S, Herring C, Simoes R, Crainic JA, Gildersleeve JC, van der Post S, Hansson GC, Fleckenstein JM.
Infect Immun. 2022 Feb 17;90(2):e0057221. doi: 10.1128/IAI.00572-21. Epub 2021 Nov 22.
PMID: 34807735

Quantifying Donor Deficits Following Nerve Transfer Surgery in Tetraplegia.

Francoisse CA, Russo SA, Skladman R, Kahn LC, Kennedy C, Stenson KC, Novak CB, Fox IK.
J Hand Surg Am. 2022 Dec;47(12):1157-1165. doi: 10.1016/j.jhsa.2022.08.014. Epub 2022 Oct 17.
PMID: 36257880

Blocking cell cycle progression through CDK4/6 protects against chronic kidney disease.

Osaki Y, Manolopoulou M, Ivanova AV, Vartanian N, Mignemi MP, Kern J, Chen J, Yang H, Fogo AB, Zhang M, Robinson-Cohen C, Gewin LS.
JCI Insight. 2022 Jun 22;7(12):e158754. doi: 10.1172/jci.insight.158754.
PMID: 35730565

Midesophageal Metastatic Disease After Treatment of Gastroesophageal Junction Adenocarcinoma.

Brotherton T, Burton S, Knoche E, Presti M.
ACG Case Rep J. 2022 Oct 6;9(10):e00869. doi: 10.14309/crj.0000000000000869. eCollection 2022 Oct.
PMID: 36212240

Characterization of uridine-cytidine kinase like-1 nucleoside kinase activity and its role in tumor growth.

Emily C Matchett 1, Elise C Ambrose 1, Jacki Kornbluth 1 2
Biochem J. 2022 Jun 17;479(11):1149-1164. doi: 10.1042/BCJ20210770.

Development and Validation of the VA Lung Cancer Mortality (VALCAN-M) Score for 90-day Mortality Following Surgical Treatment of Clinical Stage I Lung Cancer.

Heiden BT, Eaton DB Jr, Brandt WS, Chang SH, Yan Y, Schoen MW, Patel MR, Kreisel D, Nava RG, Meyers BF, Kozower BD, Puri V.
Ann Surg. 2022 Oct 17:10.1097/SLA.0000000000005725. doi: 10.1097/SLA.0000000000005725. Online ahead of print.
PMID: 36250678

The Impact of Persistent Smoking After Surgery on Long-term Outcomes After Stage I Non-small Cell Lung Cancer Resection.

Heiden BT, Eaton DB Jr, Chang SH, Yan Y, Schoen MW, Chen LS, Smock N, Patel MR, Kreisel D, Nava RG, Meyers BF, Kozower BD, Puri V.
Chest. 2022 Jun;161(6):1687-1696. doi: 10.1016/j.chest.2021.12.634. Epub 2021 Dec 14.
PMID: 34919892

TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis.

Ma X, Rawnsley DR, Kovacs A, Islam M, Murphy JT, Zhao C, Kumari M, Foroughi L, Liu H, Qi K, Diwan A, Hyrc K, Evans S, Satoh T, French BA, Margulies KB, Javaheri A, Razani B, Mann DL, Mani K, Diwan A.
JACC Basic Transl Sci. 2021 Dec 17;7(3):223-243. doi: 10.1016/j.jacbts.2021.12.002. eCollection 2022 Mar.
PMID: 35411325

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.

Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. *Diabetes Care.* 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. PMID: 35972218

Mitigating COVID-19 Vaccine Waste Through a Multidisciplinary Inpatient Vaccination Initiative.

Baumann N, Chen S, McDonald JR, Davis MH, Petroff C, McKelvy P. *J Healthc Qual.* 2022 May-Jun 01;44(3):178-183. doi: 10.1097/JHQ.0000000000000337. Epub 2022 Jan 21. PMID: 35067537

Universal masking to control healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2).

Thompson ER, Williams FS, Giacini PA, Drummond S, Brown E, Nalick M, Wang Q, McDonald JR, Carlson AL. *Infect Control Hosp Epidemiol.* 2022 Mar;43(3):344-350. doi: 10.1017/ice.2021.127. Epub 2021 Mar 29. PMID: 33775264

Stepwise Multimodality Imaging Assists in Atrial Myxoma Diagnosis and Management.

Wong KE, Mani K, Melby SJ, Hou P, Ou J. *JACC Case Rep.* 2023 Mar 15;10:101757. doi: 10.1016/j.jaccas.2023.101757. eCollection 2023 Mar 15. PMID: 36974044

Islet primary cilia motility controls insulin secretion.

Cho JH, Li ZA, Zhu L, Muegge BD, Roseman HF, Lee EY, Utterback T, Woodhams LG, Bayly PV, Hughes JW. *Sci Adv.* 2022 Sep 23;8(38):eabq8486. doi: 10.1126/sciadv.abq8486. Epub 2022 Sep 23. PMID: 36149960

Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury.

Zhou Q, Doherty J, Akk A, Springer LE, Fan P, Spasojevic I, Halade GV, Yang H, Pham CTN, Wickline SA, Pan H. *Nanomaterials (Basel).* 2022 Jan 21;12(3):336. doi: 10.3390/nano12030336. PMID: 35159680

Influences of polycyclic aromatic hydrocarbon on the epigenome toxicity and its applicability in human health risk assessment.

Durgesh Nandini Das, Nathan Ravi. *Environ Res.* 2022 Oct;213:113677. doi: 10.1016/j.envres.2022.113677. Epub 2022 Jun 14

TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma.

Theofani E, Semitekolou M, Samitas K, Mais A, Galani IE, Triantafyllia V, Lama J, Morianos I, Stavropoulos A, Jeong SJ, Andreakos E, Razani B, Rovina N, Xanthou G.
Allergy. 2022 Jul;77(7):2131-2146. doi: 10.1111/all.15221. Epub 2022 Jan 25.
PMID: 35038351

Neutrophil DREAM promotes neutrophil recruitment in vascular inflammation.

Li J, Kumari T, Barazia A, Jha V, Jeong SY, Olson A, Kim M, Lee BK, Manickam V, Song Z, Clemens R, Razani B, Kim J, Dinauer MC, Cho J.
J Exp Med. 2022 Jan 3;219(1):e20211083. doi: 10.1084/jem.20211083. Epub 2021 Nov 9.
PMID: 34751735

Autophagy in Atherosclerosis: Not All Foam Cells Are Created Equal.

Francis GA, Razani B.
Circ Res. 2022 Mar 18;130(6):848-850. doi: 10.1161/CIRCRESAHA.122.320857. Epub 2022 Mar 17.
PMID: 35298303

Unanswered questions in cancer-associated thrombosis.

Sanfilippo KM, Moik F, Candeloro M, Ay C, Di Nisio M, Lee AYY.
Br J Haematol. 2022 Sep;198(5):812-825. doi: 10.1111/bjh.18276. Epub 2022 May 25.
PMID: 35611985

Thrombosis and bleeding in hematological malignancy.

Wang TF, Leader A, Sanfilippo KM.
Best Pract Res Clin Haematol. 2022 Mar;35(1):101353. doi: 10.1016/j.beha.2022.101353. Epub 2022 Jun 16.
PMID: 36030068

Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.

Sanfilippo KM, Carson KR, Wang TF, Luo S, Edwin N, Kuderer N, Keller JM, Gage BF.
Res Pract Thromb Haemost. 2022 Jan 9;6(1):e12634. doi: 10.1002/rth2.12634. eCollection 2022 Jan.
PMID: 35028491

Venous thromboembolism and risk stratification in hematological malignancies.

Sanfilippo KM.
Thromb Res. 2022 May;213 Suppl 1:S16-S21. doi: 10.1016/j.thromres.2022.01.008. Epub 2022 May 26.
PMID: 36210555

Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy.

Sanfilippo KM, Wang TF, Carrier M, Falanga A, Gage BF, Khorana AA, Maraveyas A, Soff GA, Wells PS, Zwicker JI.
J Thromb Haemost. 2022 Aug;20(8):1920-1927. doi: 10.1111/jth.15759. Epub 2022 May 30.
PMID: 35635332

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.

Schoen MW, Carson KR, Eisen SA, Bennett CL, Luo S, Reimers MA, Knoche EM, Whitmer AL, Yan Y, Drake BF, Sanfilippo KM.

Prostate Cancer Prostatic Dis. 2022 Sep 14. doi: 10.1038/s41391-022-00588-5. Online ahead of print. PMID: 3610450

Different risks of hemorrhage in patients with elevated international normalized ratio from chronic liver disease versus warfarin therapy, a population-based retrospective cohort study.

Afzal A, Gage BF, Suhong L, Schoen MW, Korenblat K, Sanfilippo KM.

J Thromb Haemost. 2022 Jul;20(7):1610-1617. doi: 10.1111/jth.15743. Epub 2022 May 26. PMID: 35491428

Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.

Nickols NG, Mi Z, DeMatt E, Biswas K, Clise CE, Huggins JT, Maraka S, Ambrogini E, Mirsaeidi MS, Levin ER, Becker DJ, Makarov DV, Adorno Febles V, Belligund PM, Al-Ajam M, Muthiah MP, Montgomery RB, Robinson KW, Wong YN, Bedimo RJ, Villareal RC, Aguayo SM, Schoen MW, Goetz MB, Graber CJ, Bhattacharya D, Soo Hoo G, Orshansky G, Norman LE, Tran S, Ghayouri L, Tsai S, Geelhoed M, Rettig MB.

JAMA Netw Open. 2022 Apr 1;5(4):e227852. doi: 10.1001/jamanetworkopen.2022.7852. PMID: 35438754

Racial Disparities in the Surgical Treatment of Clinical Stage I Non-Small Cell Lung Cancer Among Veterans.

Heiden BT, Eaton DB Jr, Chang SH, Yan Y, Baumann AA, Schoen MW, Patel MR, Kreisel D, Nava RG, Meyers BF, Kozower BD, Puri V.

Chest. 2022 Oct;162(4):920-929. doi: 10.1016/j.chest.2022.03.045. Epub 2022 Apr 8. PMID: 35405111

Treating advanced lung cancer in older veterans with comorbid conditions and frailty.

Thomas T, Patel B, Mitchell J, Whitmer A, Knoche E, Gupta P.

Semin Oncol. 2022 Jul 3:S0093-7754(22)00044-6. doi: 10.1053/j.seminoncol.2022.06.004. Online ahead of print.

PMID: 35853764

Risks and burdens of incident diabetes in long COVID: a cohort study.

Xie Y, Al-Aly Z.

Lancet Diabetes Endocrinol. 2022 May;10(5):311-321. doi: 10.1016/S2213-8587(22)00044-4. Epub 2022 Mar 21.

PMID: 35325624

Long-term cardiovascular outcomes of COVID-19.

Xie Y, Xu E, Bowe B, Al-Aly Z.

Nat Med. 2022 Mar;28(3):583-590. doi: 10.1038/s41591-022-01689-3. Epub 2022 Feb 7.
PMID: 35132265

Risks of mental health outcomes in people with covid-19: cohort study.

Xie Y, Xu E, Al-Aly Z.

BMJ. 2022 Feb 16;376:e068993. doi: 10.1136/bmj-2021-068993.

PMID: 35172971

Impact of Socioeconomic Status on Major Amputation in Patients with Peripheral Vascular Disease and Diabetes Mellitus.

Fan RR, Gibson AK, Smeds MR, Zakhary E.

Ann Vasc Surg. 2022 Nov;87:78-86. doi: 10.1016/j.avsg.2022.03.035. Epub 2022 Apr 6.

PMID: 35398196

2023 VHA ORD Submissions Calendar

February 1st

BLR&D/CSR&D: Nominations for the Middleton Award and Barnwell Award

RR&D:

Pre-applications / Letters of Intent (LOIs)

Waiver requests for spring cycle

February 1st - March 8th

BLR&D / CSR&D Merit Review (MR) Parent award submission widow

February 15th - March 10th

RR&D MR Parent award submission widow

March 1st

HSR&D: Nominations for Promos

RR&D: Promos applications

April 15th

HSR&D: Career Development (CD) LOIs

May 1st

BLR&D/CSR&D:

LOIs for CD and Merit Review (MR) awards with LOI requirements

Off-Site Waiver Requests

Requests to exceed budget caps for Merit Review awards

RR&D: Pre-applications / LOIs and waiver requests for summer cycle

May 6th

HSR&D/QUERI: Intent to Submit deadline for summer cycle

May 11th

Waivers for exceeding budget caps

Waivers for offsite research

Waivers for IPAs in excess of 30% of personnel for Centers of Innovation (COINs) and 40% for non-COINs (Merit Review)

May 15th - June 8th

HSR&D MR Parent award submission widow

May 15th – June 10th

RR&D MR Parent award submission widow

June 1st

BLR&D/CSR&D: Requests for eligibility and/or acceptance into the Non-Clinician Intramural Research Program

August 1st

RR&D:

Pre-applications / LOIs

Waiver requests for fall cycle

August 1st – September 7th

BLR&D / CSR&D MR Parent award submission widow

August 15th – September 10th

RR&D MR Parent award submission widow

September 1st

HSR&D: Nominations for RCS and Promos

September 1st

RR&D:

Promos applications

Paul B. Magnuson Award nominations

October 15th

HSR&D: CD LOIs

November 1st

BLR&D/CSR&D:

LOIs for CD and MR awards with LOI requirements

Off-Site Waiver Requests

Requests to exceed budget caps for Merit Review Awards

RR&D:

Pre-applications / LOIs

Waiver requests for winter cycle

November 3rd

HSR&D/QUERI: Intent to Submit deadline for winter cycle

November 9th

Waivers for exceeding budget caps

Waivers for Offsite Research

Waivers for IPAs in excess of 30% of personnel for COINs and 40% for non-COINs (Merit Review)

November 15th - December 8th

HSR&D MR Parent award submission widow

November 15th - December 10th

RR&D MR Parent award submission widow

December 1st

BLR&D/CSR&D: Requests for eligibility and/or acceptance into the Non-Clinician Intramural Research Program

Research and Development Service Directory

Ziyad Al-Aly	Associate Chief of Staff / Research and Development	Ziyad.Al-Aly@va.gov
Susan Wood	Administrative Officer / Research and Development	Susan.Wood3@va.gov
Research and Development Staff, Alphabetically		
Lyric Barnes	Study Coordinator	Lyric.Barnes@va.gov
Jade Beshears	Study Coordinator	Jade.Beshears@va.gov
Charlie Bowe	Sr. Statistician	Benjamin.Bowe@va.gov
Carley Browning	Study Coordinator	Carley.Browning@va.gov
Kelley Chadwick-Mansker	Study Coordinator	Kelley.Chadwick@va.gov
Kai Chen	Research Pharmacist	Kai.Chen@va.gov
Taeyoung Choi	Clinical Epidemiology Center	Taeyoung.Choi@va.gov
John Ciconte	Statistician	John.Ciconte@va.gov
Kendrick Coleman	Administrative Officer / Research and Development Clinical Trials Unit	kendrick.coleman@va.gov
Gina Collins	Supply Technician	Gina.Collins3@va.gov
Maureen Dempsey	Study Coordinator	Maureen.Dempsey@va.gov
Bradley Devors	ADPAC	Bradley.Devors@va.gov
Daniel Eaton	Statistician	Daniel.Eaton1@va.gov
Susan Farr	Research Health Scientist	Susan.Farr@va.gov
Amy Garner	PREP Team	Amy.Garner@va.gov
Denise Garnett	Administrator / Research and Development Committee	Denise.Garnett@va.gov
Shannon Gentry	Post Award PREP Coordinator	Shannon.Gentry2@va.gov
Kyle Green	Study Coordinator	Kyle.Green@va.gov
Ray Guo	Study Coordinator	Lei.Guo@va.gov
Fahreta Hamzabegovic	Administrator / Institutional Review Board	Fahreta.Hamzabegovic@va.gov
Alysha Hunter	Management Analyst	Alysha.Hunter@va.gov
Becca Kammer	PREP Team	Rebecca.Kammer@va.gov
Janine Kampelman	Research Nurse	Janine.Kampelman@va.gov
Todd Kliche	Grants Manager	Todd.Kliche@va.gov
Jacki Kornbluth	Health Science Specialist	Jacki.Kornbluth@va.gov
Janis Kuhn	Study Coordinator	Janis.Kuhn@va.gov
Terrance Kummer	Physician	Terrance.Kummer@va.gov
Ulysses Labilles	Research Health Science Specialist	Ulysses.Labilles@va.gov
Scott Leibovich	Budget Technician	Scott.Leibovich@va.gov
John Long	Veterinarian	john.long@health.sl.u.edu
Wanda McLemore	Study Coordinator	Wanda.McLemore2@va.gov
Brittany Minor	Study Coordinator	Brittany.Minor@va.gov
Marlowe Mosley	Study Coordinator	Marlowe.Mosley1@va.gov

Research and Development Service Directory, Alphabetically (continued)

Emilee Nealy	PREP Team	Emilee.Nealy@va.gov
Jeanne Nerbonne	Research Health Scientist	Jeanne.Nerbonne@va.gov
Natalie Niceforo	Administrator / Institutional Review Board	Natalie.Niceforo@va.gov
Erin Olson	Budget Analyst	Erin.Olson@va.gov
April Phipps	Study Coordinator	April.Phipps2@va.gov
Joshua Prince	Study Coordinator	Joshua.Prince@va.gov
Sandy Prosis	Research Compliance Officer	Sandra.Prosis@va.gov
Varun Puri	Physician	Varun.Puri@va.gov
Jori Rinderer	Study Coordinator	Jori.Rinderer@va.gov
Lynn Robbins	Biologist	Lynn.Robbins@va.gov
Linda Schimmoeller	Research Nurse	Linda.Schimmoeller@va.gov
Gary Schofield	Nurse Manager	Gary.Schofield@va.gov
Allison Shafer	VREF Executive Director	Allison.Shafer@va.gov
Patrice Simpson	Study Coordinator	Patrice.Simpson@va.gov
Danielle Tate	Program Support Assistant, Clinical Trials Unit	Danielle.Tate@va.gov
Erin Torrence	Administrator / Institutional Animal Care and Use Committee & Subcommittee for Research Safety	Erin.Torrence@va.gov
Lindsey Vargo	Study Coordinator	Lindsey.Vargo@va.gov
Brooke Watkins	Study Coordinator	Brooke.Watkins@va.gov
Carolyn Williams	Program Support Assistant	carolyn.williams2@va.gov
Marie White	Research Nurse	Socorro.White@va.gov
Yan Xie	Statistician	Yan.Xie3@va.gov
Evan Xu	Clinical Epidemiology Center	Evan.Xu@va.gov
Paige Zimmerman	Technology Transfer Specialist	Paige.Zimmerman@va.gov